［1］ SUNG H,FERLAY J,SIEGER RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA:A Cancer Journal for Clinicians,2021,71(3):209-249.
［2］ KENNEDY LB,SALAMA AKS.A review of cancer immunotherapy toxicity［J］.CA:A Cancer Journal for Clinicians,2020,70(2):86-104.
［3］ HUANG S,ZHAO Q.Nanomedicine-combined immunotherapy for cancer［J］.Current Medical Chemistry,2020,27(34):5716-5729.
［4］ CASSETTA L,KITAMURA T.Macrophage targeting:opening new possibilities for cancer immunotherapy［J］.Immunology,2018,155(3):285-293.
［5］ MERLO LM,PEPPER JW,REID BJ,et al.Cancer as an evolutionary and ecological process［J］.Nature Reviews Cancer,2006,6(12):924-935.
［6］ XIAO Y,YU D.Tumor microenvironment as a therapeutic target in cancer［J］.Pharmacology & Therapeutics,2021,221(4):107753.
［7］ GORDON S,PLUDDEMANN A.The mononuclear phagocytic system.Generation of diversity［J］.Frontiers in Immunology,2019,10:1893.
［8］ MANTOVANI A,MARCHESI F,MALESCI A,et al.Tumour-associated macrophages as treatment targets in oncology［J］.Nature Reviews Clinical Oncology,2017,14(7):399-416.
［9］ CASSETTA L,POLLARD JW.Targeting macrophages:therapeutic approaches in cancer［J］.Nature Reviews Drug Discovery,2018,17(12):887-904.
［10］ BISWAS SK,MANTOVANI A.Mantovani,macrophage plasticity and interaction with lymphocyte subsets:cancer as a paradigm［J］.Nature Immunology,2010,11(10):889-896.
［11］ PAN Y,YU Y,WANG X,et al.Tumor-associated macrophages in tumor immunity［J］.Frontiers in Immunology,2020,11:583084.
［12］ GRIESS B,MIR S,DATTA K,et al.Scavenging reactive oxygen species selectively inhibits M2 macrophage polarization and their pro-tumorigenic function in part,via Stat3 suppression［J］.Free Radical Biology & Medicine,2020,147:48-60.
［13］ NGAMBENJAWONG C,GUSTAFSON HH,PUN SH.Progress in tumor-associated macrophage (TAM)-targeted therapeutics［J］.Advance Drug Delivery Reviews,2017,114:206-221.
［14］ MERTENS C,AKAM EA,REHWALD C,et al.Intracellular iron chelation modulates the macrophage iron phenotype with consequences on tumor progression［J］.PLoS One,2016,11(11):e0166164.
［15］ XIANG W,SHI R,KANG X,et al.Monoacylglycerol lipase regulates cannabinoid receptor 2-dependent macrophage activation and cancer progression［J］.Nature Communication,2018,9(1):2574.
［16］ PALMIERI EM,MENGA A,MARTIN-PEREZ R,et al.Pharmacologic or genetic targeting of glutamine synthetase skews macrophages toward an M1-like phenotype and inhibits tumor metastasis［J］.Cell Repors,2017,20(7):1654-1666.
［17］ WU K,LIN K,LI X,et al.Redefining tumor-associated macrophage subpopulations and functions in the tumor microenvironment［J］.Frontiers in Immunology,2020,11:1731.
［18］ PITTET MJ,MICHIELIN O,MIGLIORINI D.Clinical relevance of tumour-associated macrophages［J］.Nature Reviews Clinical Oncology,2022,19(6):402-421.
［19］ CASSETTA L,FRAGKOGIANNI S,SIMS AH,et al.Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming,biomarkers,and therapeutic targets［J］.Cancer Cell,2019,35(4):588-602.
［20］ YUNNA C,MENGRU H,LEI W,et al.Macrophage M1/M2 polarization［J］.European Journal of Pharmacology,2020,877:173090.
［21］ SAUNG MT,MUTH S,DING D,et al.Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer［J］.Journal for Immunotherapy of Cancer,2018,6(1):118.
［22］ KAI K,IWAMOTO T,ZHANG D,et al.CSF-1/CSF-1R axis is associated with epithelial/mesenchymal hybrid phenotype in epithelial-like inflammatory breast cancer［J］.Scientific Reports,2018,8(1):9427.
［23］ RYDER M,GILD M,HOHL TM，et al.Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression［J］.PLoS One,2013,8(1):e54302.
［24］ QIAO S,CHENG Y,LIU M,et al.Chemoattractants driven and microglia based biomimetic nanoparticle treating TMZ-resistant glioblastoma multiforme［J］.Journal of Control Release,2021,336:54-70.
［25］ DING L,WANG Q,MARTINCUKS A,et al.STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer［J］.Journal for Immunotherapy of Cancer,2023,11(1):5627.
［26］ HUANG Y,SUN H,GUO P.Research progress of tumor microenvironment targeted therapy for clear cell renal cell carcinoma［J］.Cancer Control,2023，30(5):10732748231155700.
［27］ JAHCHAN NS,MUJAL AM,POLLACK JL,et al.Tuning the tumor myeloid microenvironment to fight cancer［J］.Frontiers in Immunology,2019,10:1611.
［28］ REILLEY MJ,MORROW B,AGER CR,et al.TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma［J］.Journal for Immunotherapy of Cancer,2019,7(1):323.
［29］ SO EY,OUCHI T.The application of Toll like receptors for cancer therapy［J］.International Journal of Biological Science,2010,6(7):675-681.
［30］ VIDYARTHI A,KHAN N,AGNIHOTRI T,et al.TLR-3 stimulation skews M2 macrophages to M1 through IFN-αβ signaling and restricts tumor progression［J］.Frontiers in Immunology,2018,9(6):1650-1657.
［31］ ZHENG JH,NGUYEN VH,JIANG SN,et al.Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin［J］.Science Translational Medicine,2017,9(376):9537-9541.
［32］ RODELL CB,ARLAUCKAS SP,CUCCARESE MF,et al.TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy［J］.Nature Biomedical Engineering,2018,2(8):578-588.
［33］ SATO-KANEKO F,YAO S,AHMADI A,et al.Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer［J］.JCI Insight,2017,2(18):e93397.
［34］ DI S,ZHOU M,PAN Z,et al.Combined adjuvant of poly I:C improves antitumor effects of CAR-T cells［J］.Frontiers in Oncology,2019，9(17):241.
［35］ QIAN BZ,POLLARD JW.Macrophage diversity enhances tumor progression and metastasis［J］.Cell,2010,141(1):39-51.
［36］ SANFORD DE,BELT BA,PANNI RZ,et al.Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer:a role for targeting the CCL2/CCR2 axis［J］.Clininal Cancer Research,2013,19(13):3404-3415.
［37］ NYWENING TM,WANG-GILLAM A,SANFORD DE,et al.Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer:a single-centre,open-label,dose-finding,non-randomised,phase 1b trial［J］.Lancet Oncology,2016,17(5):651-662.
［38］ BRANA I,CALLES A,LORUSSO PM,et al.Carlumab,an anti-C-C chemokine ligand 2 monoclonal antibody,in combination with four chemotherapy regimens for the treatment of patients with solid tumors:an open-label,multicenter phase 1b study［J］.Targeted Oncology,2015,10(1):111-123.
［39］ LOYHER PL,ROCHEFORT J,BAUDESSON DE CHANVILLE C,et al.CCR2 influences T regulatory cell migration to tumors and serves as a biomarker of cyclophosphamide sensitivity［J］.Cancer Res,2016,76(22):6483-6494.
［40］ PIENTA KJ,MACHIELS JP,SCHRIJVERS D,et al.Phase 2 study of carlumab (CNTO 888),a human monoclonal antibody against CC-chemokine ligand 2 (CCL2),in metastatic castration-resistant prostate cancer［J］.Investigational New Drugs,2013,31(3):760-768.
［41］ DENARDO DG,BRENNAN DJ,REXHEPAJ E,et al.Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy［J］.Cancer Discovery,2011,1(1):54-67.
［42］ PYONTECK SM,AKKARI L,SCHUHMACHER AJ,et al.CSF-1R inhibition alters macrophage polarization and blocks glioma progression［J］.Nature Medicine,2013,19(10):1264-1272.
［43］ STRACHAN DC,RUFFELL B,OEI Y,et al.CSF-1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells［J］.Oncoimmunology,2013，2(12):e26968.
［44］ GOMEZ-ROCA CA,ITALIANO A,LE TOURNEAU C,et al.Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages［J］.Annals of Oncology,2019,30(8):1381-1392.
［45］ MOUGHON DL,HE H,SCHOKRPUR S,et al.Macrophage blockade using CSF1R inhibitors reverses the vascular leakage underlying malignant ascites in late-stage epithelial ovarian cancer［J］.Cancer Res,2015,75(22):4742-4752.
［46］ QUAIL DF,BOWMAN RL,AKKARI L,et al.The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas［J］.Science,2016,352(6288):aad3018.
［47］ VAN ACKER HH,ANGUILLE S,WILLEMEN Y,et al.Bisphosphonates for cancer treatment:Mechanisms of action and lessons from clinical trials［J］.Pharmacol Ther,2016,158(6):24-40.
［48］ ZHANG W,ZHU XD,SUN HC,et al.Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects［J］.Clinical Cancer Research,2010,16(13):3420-3430.
［49］ PIAGGIO F,KONDYLIS V,PASTORINO F,et al.A novel liposomal Clodronate depletes tumor-associated macrophages in primary and metastatic melanoma:Anti-angiogenic and anti-tumor effects［J］.Journal of Control Release,2016，223:165-177.
［50］ PENNANEN SJ,SUNG JL,SHAPOSHBIK Z,et al.Effect of liposomal and free bisphosphonates on the IL-1 beta,IL-6 and TNF alpha secretion from RAW 264 cells in vitro［J］.Pharmaceutical Research,1995,12(6):916-922.
［51］ ALLAVENA P,SIGNORELLI M,CHIEPPA M,et al.Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin):inhibition of macrophage differentiation and cytokine production［J］.Cancer Research,2005,65(7):2964-2971.
［52］ GERMANO G,FRAPOLLI R,SIMONE M,et al.Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells［J］.Cancer Research,2010,70(6):2235-2244.
［53］ ZHANG SY,SONG XY,LI Y,et al.Role of macrophage targeting in the antitumor activity of trabectedin［J］.Cancer Cell,2013,23(2):249-962.
［54］ ZHANG JQ,ZENG S,VITIELLO GA,et al.Macrophages and CD8+T cells mediate the antitumor efficacy of combined CD40 ligation and imatinib therapy in gastrointestinal stromal tumors［J］.Cancer Immunology Research,2018,6(4):434-447.
［55］ GLADUE RP,PARADIS T,COLE SH,et al.The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice［J］.Cancer Immunol Immunother,2011,60(7):1009-1017.
［56］ LEWIS TS,MCCORMICK RS,EMMERTON K,et al.Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma［J］.Clinical Cancer Research,2011,17(14):4672-4681.
［57］ CHOWDHURY F,JOHNSON PW,GLENNIE MJ,et al.Ex vivo assays of dendritic cell activation and cytokine profiles as predictors of in vivo effects in an anti-human CD40 monoclonal antibody ChiLob 7/4 phase I trial［J］.Clinical Cancer Research,2014,2(3):229-240.
［58］ JOHNSON P,CHALLIS R,CHUWDHURY F,et al.Clinical and biological effects of an agonist anti-CD40 antibody:A Cancer Research UK phase I study［J］.Clinical Cancer Research,2015,21(6):1321-1328.
［59］ MURATA Y,KOTANI T,OHNISHI H,et al.The CD47-SIRPα signalling system:its physiological roles and therapeutic application［J］.Journal of Biochemistry,2014,155(6):335-344.
［60］ NOMAN MZ,VAN MOER K,MARANI V,et al.CD47 is a direct target of SNAI1 and ZEB1 and its blockade activates the phagocytosis of breast cancer cells undergoing EMT［J］.Oncoimmunology,2018,7(4):e1345415.
［61］ ZANG X,ZHANG X,HU H,et al.Targeted delivery of zoledronate to tumor-associated macrophages for cancer immunotherapy［J］.Molecular Pharmacology,2019,16(5):2249-2258.
［62］ WEISKOPF K,WEISSMAN IL.Macrophages are critical effectors of antibody therapies for cancer［J］.MAbs,2015,7(2):303-310.
［63］ RING NG,HERNDLER-BRANFSTETTER D,WEISKOPF K,et al.Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity［J］.Proceedings of the National Academy of Scicences of the United States of Amercica,2017,114(49):10578-10585.
［64］ LIU J,WANG L,ZHAO F,et al.Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential［J］.PLoS One,2015,10(9):e0137345.
［65］ NARLA RK,MODI H,BAUER D,et al.Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody［J］.Cancer Immunol Immunother,2022，71(2):473-489.
［66］ QUERFELD C,THOMPSON JA,TAYLOR MH,et al.Intralesional TTI-621,a novel biologic targeting the innate immune checkpoint CD47,in patients with relapsed or refractory mycosis fungoides or Sézary syndrome:a multicentre,phase 1 study［J］.Lancet Haematology,2021,8(11):808-817.
［67］ LAKHANI NJ,CHOW LQM,GAINOR JF,et al.Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01):a first-in-human,open-label,multicentre,phase 1 dose-escalation and dose-expansion study［J］.Lancet Oncology,2021,22(12):1740-1751.
［68］ BARKAL AA,BREWER RE,MARKOVIC M,et al.CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy［J］.Nature,2019,572(7769):392-396.
［69］ BARKAL AA,WEISKOPF K,KAO KS,et al.Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy［J］.Nature Immunology,2018,19(1):76-84.
［70］ MUNAGALA R,AQIL F,JEYABALAN J,et al.Exosomal formulation of anthocyanidins against multiple cancer types［J］.Cancer Letters,2017，393:94-102.
［71］ GOMARI H,FOROUZENDEH MOGHADAM M,SOLEIMANI M.Targeted cancer therapy using engineered exosome as a natural drug delivery vehicle［J］.Onco Targets and Therapy,2018,11(5):5753-5762.
［72］ SU MJ,AWSARI H,AMIJI M.Pancreatic cancer cell exosome-mediated macrophage reprogramming and the role of microRNAs 155 and 125b2 transfection using nanoparticle delivery systems［J］.Scientific Reports,2016,6(3):30110.
［73］ TRIVEDI M,TALEKAR M,SHAH P,et al.Modification of tumor cell exosome content by transfection with wt-p53 and microRNA-125b expressing plasmid DNA and its effect on macrophage polarization［J］.Oncogenesis,2016,5(8):e250.
［74］ KAMERKAR S,LENG C,BURENKOVA O,et al.Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity［J］.Science Advances,2022,8(7):eabj7002.
［75］ KANEDA MM,MESSER KS,RALAINIRINA N,et al.PI3Kγ is a molecular switch that controls immune suppression［J］.Nature,2016,539(7629):437-442.
［76］ LARSON RC,MAUS MV.Recent advances and discoveries in the mechanisms and functions of CAR T cells［J］.Nature Reviews Cancer,2021,21(3):145-161.
［77］ ZHANG L,TIAN L,DAI X,et al.Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions［J］.J Hematol Oncology,2020,13(1):153.
［78］ ZHANG W,LIU L,SU H,et al.Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix［J］.British Journal of Cancer,2019,121(10):837-845.
［79］ KLICHINSKY M,RUELLA M,SHESTOVA O,et al.Human chimeric antigen receptor macrophages for cancer immunotherapy［J］.Nature Biotechnology,2020,38(8):947-953.